Lena Jendeberg

Director/Miembro de la Junta en ATTANA AB .

60 años

Health Technology

Health Services

Consumer Services

Cargos activos de Lena Jendeberg

Empresas	Cargo	Inicio	Fin
ATTANA AB	Director/Miembro de la Junta	01/01/2018	-

Empresas	Cargo	Inicio	Fin
Modus Therapeutics AB Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.	Corporate Officer/Principal	01/01/2016	-

Royal Institute of Technology

Doctorate Degree

Internacional

Suecia

Operativa

Corporate Officer/Principal	1
Director/Board Member	1
Doctorate Degree	1

Sectorial

Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Empresas cotizadas	1
ATTANA AB	Health Services

Empresas privadas	1
Modus Therapeutics AB Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden.	Health Technology

Empresas privadas

Health Technology